Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients

@inproceedings{Lin2012MechanismsOR,
  title={Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients},
  author={Luping Lin and Trever G Bivona},
  booktitle={Chemotherapy research and practice},
  year={2012}
}
The epidermal growth factor receptor (EGFR) is a well-characterized oncogene that is frequently activated by somatic kinase domain mutations in non-small cell lung cancer (NSCLC). EGFR TKIs are effective therapies for NSCLC patients whose tumors harbor an EGFR activating mutation. However, EGFR TKI treatment is not curative in patients because of both primary and secondary treatment resistance. Studies over the last decade have identified mechanisms that drive primary and secondary resistance… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer

Medical science monitor : international medical journal of experimental and clinical research • 2016
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 90 references

Advances in targeting IKK and IKK-related kinases for cancer therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2008
View 13 Excerpts
Highly Influenced

Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2011
View 1 Excerpt

Breast cancer statistics, 2011.

CA: a cancer journal for clinicians • 2011
View 1 Excerpt

Similar Papers

Loading similar papers…